A First in its Class Therapeutic in the GI System Shows Promise for ASD
In a recent issue of Nature Medicine, researchers associated with Axial Therapeutics reported first preliminary clinical trial evidence that AB-2004, a first-in-class molecular therapeutic that prevents the absorption of neuroactive microbial metabolites from...
Why CANDID Focuses on GI Disorders
Prevalence There is an increased prevalence of gastrointestinal disorders (GI) in patients with neurodevelopmental disorders (NDDs) and autism. Yet our current estimates of prevalence of functional gastrointestinal disorders (FGIDs) in these...
